|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 240 Madison Avenue |
Address2 |
|
| City | MEMPHIS |
State | TN |
Zip Code | 38103-2398 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Chattanooga |
State | TN |
Zip Code | 37402 |
Country | USA |
|
5. Senate ID# 6440-12
|
||||||||
|
6. House ID# 334350000
|
||||||||
| TYPE OF REPORT | 8. Year | 2026 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Tavarski Hughes |
Date | 4/17/2026 4:35:22 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Affordable Care Act (ACA), ACA subsidies and tax credits; Telehealth/telehealth flexibilities, ACA Fraud; Transparency in Coverage; Exchanges; Rural Healthcare; Prior Authorization (PA); Managed Care Organizations; Federal Budget Process; Hospital Billing/Consolidation; Maternal Health; Individual Marketplace Program Integrity; EAPTC Extension; HealthCare Affordability; Health Savings Accounts
S.2355 - Patients Deserve Price Tags Act
To amend the Public Health Service Act to provide for hospital and insurer price transparency.
Sponsor: Sen. Roger Marshall
H.R. 4710 - No Surprises Act Enforcement Act
To amend title XXVII of the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Cide if 1986 to increase penalties for group health plans, health insurance issuers and nonparticipating providers or facilities for practices that violate balance billing requirements, and for other purposes.
Sponsor: Rep Gergory Murphy
S. 2420 - No Surprises Act Enforcement Act
To amend title XXVII of the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Cide if 1986 to increase penalties for group health plans, health insurance issuers and nonparticipating providers or facilities for practices that violate balance billing requirements, and for other purposes.
Sponsor: Sen. Roger Marshall
S. 4027- Health Competition For Better Care Act
To ban anticompetitive terms in facility and insurance contracts that limit access to higher quality, lower cost care
Sponsor: Sen Jon Justed
H.R. 6248 Healthy Competition for Better Care Act
To ban anticompetitive terms in facility and insurance contracts that limit access to higher quality, lower cost care
Sponsor: Rep Jodey Arrington
H.R. 2079 - Insurance Fraud Accountability Act
To amend the Patient Protection and Affordable Care Act to reduce fraudulent enrollments in qualified health plans, and for other purposes.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tavarski |
Hughes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare Advantage (MA) and MA Rate Notice; Medicaid Cuts; Site Neutral Payment reform; MA Reform
S. 1105 - No UPCODE Act
To amend title XVIII of the Social Security Act to improve risk adjustment under Medicare Advantage
H.R. 842 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
To amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Sponsor: Rep Jodey Arrington
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tavarski |
Hughes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Pharmacy Benefit Managers; Prescription Drug Cost; Delinking of Pharmacy; Generic Access; Direct to Consumer Marketing; Pay to Play; Patents
S. 3014 - Ensuring Timely Access to Generics Act of 2025
To amend the Federal Food, Drug and Cosmetic Act with respect to citizen petitions.
Sponsor: Sen. Jeanne Shaheen
S.1040 - Drug Competition Enhancement Act
A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
Sponsor: Sen. John Cornyn
S.1095 - Stop STALLING Act
A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition and facilitate the effective review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
Sponsor: Sen Amy Klobuchar
S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of o generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Sponsor: Sen Amy Klobuchar
H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025
TO amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes.
Sponsor: Rep Joe Neguse
S1097 - Interagency Patent Coordination and Improvement Act of 2025
TO amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes.
Sponsor: S. Richard Durbin
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tavarski |
Hughes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |